`
The global AI in cancer diagnostics market size 2026 was valued at USD 1.06 billion in 2025 and is projected to grow from USD 1.28 billion in 2026 to USD 9.56 billion by 2034, registering a remarkable CAGR of 28.58% during the forecast period. North America led the market in 2025, commanding a share of 38.67%.
This growth is fueled by rising cancer incidence globally, increasing demand for scalable diagnostic tools, and the rapid digitization of healthcare workflows across imaging, digital pathology, and genomics. As hospitals and laboratories modernize their data systems, AI solutions are being adopted to support consistent reads, faster prioritization of high-risk cases, and standardized reporting.
Key Market Drivers
Rising Cancer Incidence is the foremost growth driver. As patient volumes surge, radiology and pathology departments face mounting workload pressure. AI tools help triage large caseloads, detect suspicious findings earlier, and standardize diagnostic interpretations — without requiring a proportional increase in specialist headcount. A landmark example: in February 2025, the U.K. government launched a trial involving nearly 700,000 women to test AI tools for earlier cancer detection through NHS screening programs.
Biomarker Scoring Adoption is another major trend. As biomarker testing expands in oncology, AI tools are increasingly used to standardize scoring of markers such as HER2, reduce variability among pathologists, and speed up reporting — especially in high-volume diagnostic labs.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/ai-in-cancer-diagnostics-market-115859
Market Restraints & Challenges
Regulatory complexity poses a significant barrier. Unlike consumer software, regulated healthcare AI cannot be updated freely — each model change requires additional documentation, testing, and regulatory submissions, creating longer release cycles and higher compliance costs.
Reimbursement uncertainty is another critical challenge. Many hospitals hesitate to invest in AI diagnostics unless costs can be clearly recovered through payer coverage. When coverage rules are unclear or vary by region, AI is treated as an added expense rather than a standard-of-care tool, slowing procurement and extending vendor sales cycles — even when clinical performance is strong.
Segmentation Highlights
By Component: The software segment held the largest market share, as hospitals and networks prioritize scalable AI platforms that integrate into PACS and pathology viewers. The services segment is growing at a CAGR of 22.75%.
By Technology: Computer vision dominates, underpinning most imaging-based diagnostic AI — enabling detection, segmentation, and quantification of suspicious findings from scans and pathology slides. The natural language processing segment is the fastest-growing, projected at a CAGR of 32.25%.
By Modality: Liquid biopsies led the market in 2025, driven by demand for minimally invasive testing and AI's role in interpreting complex molecular signals from blood-based assays. Digital pathology AI is the fastest-growing modality, at a CAGR of 32.08%.
By Application: Screening support accounted for the largest share, as high screening volumes demand tools that improve reading efficiency and standardize outcomes across sites.
By Cancer Type: Breast cancer held significant market share due to high-volume mammography screening programs. The lung cancer segment is projected to grow at a CAGR of 31.24%.
By Deployment: Cloud-based deployments led the market, offering scalability, simplified updates, and centralized governance across multi-site networks.
By End User: Hospitals and ASCs dominated, as they control the largest share of diagnostic decision-making and face the greatest pressure on throughput and turnaround times.
Regional Outlook
- North America leads globally, driven by strong hospital purchasing power and commercialized AI solutions for high imaging volumes.
- Europe is the second-fastest-growing region at a CAGR of 26.40%, supported by national health system investments in interoperable diagnostic IT.
- Asia Pacific is the third-largest region, with China projected at USD 0.11 billion and India at USD 0.03 billion by 2026, growing rapidly due to rising cancer burden and expanding diagnostic infrastructure.
Competitive Landscape
The market is highly consolidated, with key players including Aidoc Medical, Lunit Inc., Paige.AI, Ibex Medical Analytics, iCAD, Inc., and ScreenPoint Medical. These companies are aggressively pursuing strategic partnerships, new product launches, and regulatory approvals to strengthen their positions. Notable 2025–2026 developments include FDA premarket approval of Perimeter Medical Imaging AI's Claire device for intraoperative breast cancer margin assessment, and PathAI's deployment of its AISight Dx platform at Moffitt Cancer Center.
`
Top comments (0)